ArticleACS applied materials & interfaces2025
Development of a Tunable Dextran-PCL Biomaterial Photoink for High-Resolution DLP 3D Printing in Biomedical Applications.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital light processing (DLP) is a technique that offers higher printing speeds and high spatial resolution compared to other additive manufacturing techniques. However, in biomedical applications, the biomaterials used do not provide a good balance between biocompatibility, mechanical performance, and controlled degradation. To overcome these limitations, this study aims to develop a biomaterial photoink formulation using two FDA-approved polymers. Dextran, which has high biocompatibility, was modified with glycidyl methacrylate to introduce photoreactive groups, and poly(ε-caprolactone) (PCL), a biodegradable synthetic polymer known for its mechanical reinforcement properties and slower degradation rate, was functionalized with 2-isocyanatoethyl methacrylate. To optimize the formulation, various parameters were systematically investigated, including different polymer concentrations (10-40% w/v), concentrations of photoabsorber (0.075-0.2%) and photoinitiator (LAP) (0.3-1.25%), exposure time (13-21 s), and light intensity (45-65%). Once the optimal composition of the biomaterial photoink was determined, the effect of different polymer contents on the physicochemical, mechanical, and cytotoxic properties of the printed structures was investigated. It was found that increasing the proportion of PCL in the biomaterial photoink can lead to a slower degradation rate, reduced swelling capacity, and improved mechanical properties; however, cytocompatibility was negatively affected after 14 days of indirect contact. Direct cytotoxicity testing revealed cytocompatibility after 3 days. This study enabled the development of a highly tunable biomaterial photoink that can be adapted to different biomedical application requirements. The optimized biomaterial photoink exhibited good mechanical properties, lower viscosity, and excellent printability, enabling the printing of complex geometries (e.g., tubes), including hollow structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.